by Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder characterized by poor control of blood pressure and bodily movements along with varying degrees of Parkinsonism including rigidity, tremor and difficulty in walking. While there is no cure yet for MSA, it is being actively treated with medications and therapies that can help manage symptoms like tremor, muscle rigidity, dysautonomia and loss of mobility. Advances in understanding the pathophysiology and genetics of MSA offer promise for targeted disease-modifying therapies.
The Multiple System Atrophy (MSA) Market is estimated to be valued at US$ 137.3 Mn in 2024 and is expected to exhibit a CAGR of 4.4% over the forecast period 2024-2031.
Key players operating in the Multiple System Atrophy (MSA) are Chelsea Therapeutics International, Ltd., Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, Theravance Biopharma, Inc. and Among Others.
Key Takeaways
Key players related content comprises Chelsea Therapeutics International, Ltd., Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, Theravance Biopharma, Inc. and others. The growing geriatric population and increasing prevalence of neurodegenerative disorders is propelling the demand for MSA treatment. Moreover, favorable government funding for research and development activities along with rising investment by biopharmaceutical companies are fueling the growth of the global MSA market.
The growing demand in the market is driven by factors such as rising geriatric population coupled with increasing prevalence of Parkinson’s disease and Alzheimer’s disease. Moreover, growing awareness regarding neurodegenerative disorders and availability of various treatment options is also contributing to the market growth.
The global expansion of the market is facilitated by increasing investment in research & development of novel treatment therapies along with strengthening distribution channels across various regions. Moreover, advancements in brain imaging technologies to detect MSA more accurately along with ongoing clinical trials are further supporting the global expansion of Multiple System Atrophy treatment market.
Market Key Trends
Rise in research funding and partnership activities is one of the key trends being witnessed in the Multiple System Atrophy (MSA) Market. Several non-profit organizations as well as biopharmaceutical companies are increasingly investing in MSA-focused research. This is attributed to growing prevalence of the disease along with lack of approved effective treatment options. Moreover, partnerships between research institutions, academia and companies help in fast-tracking drug development and commercialization process, thereby facilitating entry of novel therapies in the market.
Porter’s Analysis
Threat of new entrants: Low barriers to entry as research and development of new drugs is difficult and risky.
Bargaining power of buyers: Moderate bargaining power as prevalence of MSA is low and patients have limited treatment options.
Bargaining power of suppliers: High bargaining power for pharmaceutical companies as research in rare diseases is challenging to conduct.
Threat of new substitutes: Low threat as there are limited treatment options currently available for MSA.
Competitive rivalry: Intense competitive rivalry amongst existing players to develop new treatment options and gain more market share.
Geographical Regions
North America represents the most concentrated region for the multiple system atrophy market in terms of value. This is attributed to growing research activities to develop new treatment options, presence of major pharmaceutical companies, and increasing healthcare expenditure in the US and Canada.
Asia Pacific is anticipated to be the fastest growing region over the forecast period owing to rising prevalence of MSA due to aging population, growing healthcare spending, and strengthening research scenario in countries like China, India, and Japan.
What Are The Key Data Covered In This Multiple System Atrophy (MSA) Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Multiple System Atrophy (MSA) ‘s growth between 2024 and 2031.
:- Accurate calculation of the size of the Multiple System Atrophy (MSA) and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Multiple System Atrophy (MSA) Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Multiple System Atrophy (MSA) vendors
FAQ’s
Q.1 What are the main factors influencing the Multiple System Atrophy (MSA) ?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Multiple System Atrophy (MSA) companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Multiple System Atrophy (MSA) ’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
About Author - Vaagisha Singh
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups. LinkedIn
